{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:05:36Z","timestamp":1790611536826,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T00:00:00Z","timestamp":1648857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T00:00:00Z","timestamp":1648857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with type 2 diabetes mellitus (T2DM) are susceptible to developing symptomatic peripheral arterial disease (PAD). As a proven vasodilator and antiplatelet agent, the efficiency of Beraprost sodium (BPS) on the prevention of arteries occlusion and stiffness in T2DM patients with PAD has not yet been fully investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From July 2010 to April 2012, 64 Patients enrolled were randomly assigned to the combined therapy group (<jats:italic>n<\/jats:italic>=32), which received combination therapy with BPS (60 \u03bcg\/day) and aspirin (100 mg\/day), or to the control group (<jats:italic>n<\/jats:italic>=32), which only received aspirin (100 mg\/day). After randomization, the patients were followed up at years 0, 1, 2, 3, 4, and 5 with the evaluation of carotid intima-media thickness (CIMT), pulse wave velocity (PWV), inner artery diameter, stenosis rate, and medial arterial calcification (MAC) of lower limb arteries via high-resolution ultrasound measurement. Adverse events were also recorded in each visit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was no significant change of the CIMT during the follow-up in both groups when compared to the baseline. Similar results were also observed in the PWV measurement. Significantly increases in the inner artery diameter of the dorsal pedal artery and posterior tibial artery were observed in patients with BPS and aspirin administration during the follow-up. Patients in the combined therapy group experienced marked improvement of MAC in the dorsal pedal artery and posterior tibial artery at the end of the follow-up. No significant difference in the adverse events was found between the combined therapy group and the aspirin group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The combined therapy of BPS and aspirin showed a protective effect on arteries occlusion and stiffness in T2DM patients with PAD, along with a significant improvement of inner artery diameter and MAC in lower limbs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\">http:\/\/www.chictr.org.cn<\/jats:ext-link>, ChiCTR-TRC-10000919. Prospectively registered on 2010\/06\/29.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-01007-5","type":"journal-article","created":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T20:11:06Z","timestamp":1648930266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ultrasonography evaluation on the protective effect of combination therapy of beraprost sodium and aspirin on arteries occlusion and stiffness in patients with type 2 diabetes mellitus - a prospective, randomized study"],"prefix":"10.1186","volume":"22","author":[{"given":"Xian","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,2]]},"reference":[{"issue":"11","key":"1007_CR1","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","volume":"286","author":"AT Hirsch","year":"2001","unstructured":"Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317\u201324.","journal-title":"JAMA"},{"issue":"5","key":"1007_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2005.09.065","volume":"47","author":"SP Marso","year":"2006","unstructured":"Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1007_CR3","unstructured":"Madonna R, Pieragostino D, Balistreri CR, et al. Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage. Vascul Pharmacol. 2018:S1537-1891(17)30322-1. Epub ahead of print."},{"issue":"5","key":"1007_CR4","first-page":"306","volume":"88","author":"DR Hennion","year":"2013","unstructured":"Hennion DR, Siano KA. Diagnosis and treatment of peripheral arterial disease. Am Fam Physician. 2013;88(5):306\u201310.","journal-title":"Am Fam Physician"},{"issue":"1","key":"1007_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/00003495-200262010-00005","volume":"62","author":"EB Melian","year":"2002","unstructured":"Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs. 2002;62(1):107\u201333.","journal-title":"Drugs"},{"issue":"3","key":"1007_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/pr.111.004770","volume":"64","author":"BH Majed","year":"2012","unstructured":"Majed BH, Khalil RA. Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev. 2012;64(3):540\u201382.","journal-title":"Pharmacol Rev"},{"key":"1007_CR7","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3389\/fphar.2018.01518","volume":"9","author":"F Fan","year":"2018","unstructured":"Fan F, Tian H, Geng J, et al. Mechanism of Beraprost Effects on Pulmonary Hypertension: Contribution of Cross-Binding to PGE2 Receptor 4 and Modulation of O (2) Sensitive Voltage-Gated K(+) Channels. Front Pharmacol. 2018;9:1518.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1007_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s12325-013-0030-7","volume":"30","author":"T Arai","year":"2013","unstructured":"Arai T. Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. Adv Ther. 2013;30(5):528\u201340.","journal-title":"Adv Ther"},{"issue":"1","key":"1007_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3400\/avd.oa.13-00092","volume":"7","author":"S Awsakulsutthi","year":"2014","unstructured":"Awsakulsutthi S, Punpho K, Mamom J, Baikrut P, Yingchoorod P. Beraprost sodium for chronic diabetic foot ulcer: a randomized controlled trial in thammasat university hospital. Ann Vasc Dis. 2014;7(1):40\u20135.","journal-title":"Ann Vasc Dis"},{"issue":"1","key":"1007_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jacl.2009.11.004","volume":"4","author":"L Liviakis","year":"2010","unstructured":"Liviakis L, Pogue B, Paramsothy P, Bourne A, Gill EA. Carotid intima-media thickness for the practicing lipidologist. J Clin Lipidol. 2010;4(1):24\u201335.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"1007_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.echo.2007.11.011","volume":"21","author":"JH Stein","year":"2008","unstructured":"Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93\u2013111 quiz 89-90.","journal-title":"J Am Soc Echocardiogr"},{"issue":"12","key":"1007_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/jhh.2013.41","volume":"27","author":"BM McCarthy","year":"2013","unstructured":"McCarthy BM, Vaughan CJ, O'Flynn B, Mathewson A, C \u00d3M. An examination of calibration intervals required for accurately tracking blood pressure using pulse transit time algorithms. J Hum Hypertens. 2013;27(12):744\u201350.","journal-title":"J Hum Hypertens"},{"issue":"12","key":"1007_CR13","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1161\/01.STR.0000147037.12223.d5","volume":"35","author":"DE Hyde","year":"2004","unstructured":"Hyde DE, Fox AJ, Gulka I, et al. Internal carotid artery stenosis measurement: comparison of 3D computed rotational angiography and conventional digital subtraction angiography. Stroke. 2004;35(12):2776\u201381.","journal-title":"Stroke"},{"issue":"1","key":"1007_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1148\/radiol.12112440","volume":"265","author":"KH Liu","year":"2012","unstructured":"Liu KH, Chu WC, Kong AP, et al. US assessment of medial arterial calcification: a sensitive marker of diabetes-related microvascular and macrovascular complications. Radiology. 2012;265(1):294\u2013302.","journal-title":"Radiology"},{"issue":"2","key":"1007_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4055\/cios.2013.5.2.145","volume":"5","author":"HS Yoon","year":"2013","unstructured":"Yoon HS, Choi WJ, Sung IH, Lee HS, Chung HJ, Lee JW. Effects of Beraprost sodium on subjective symptoms in diabetic patients with peripheral arterial disease. Clin Orthop Surg. 2013;5(2):145\u201351.","journal-title":"Clin Orthop Surg"},{"issue":"1","key":"1007_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/000331970205300102","volume":"53","author":"T Toyota","year":"2002","unstructured":"Toyota T, Oikawa S. Effects of beraprost sodium (Dorner) in patients with diabetes mellitus complicated by chronic arterial obstruction. Angiology. 2002;53(1):7\u201313.","journal-title":"Angiology"},{"key":"1007_CR17","first-page":"429","volume":"8","author":"K Utsunomiya","year":"2012","unstructured":"Utsunomiya K. Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance. Vasc Health Risk Manag. 2012;8:429\u201336.","journal-title":"Vasc Health Risk Manag"},{"issue":"6s","key":"1007_CR18","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","volume":"69","author":"MS Conte","year":"2019","unstructured":"Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6s):3S\u2013125S.e40.","journal-title":"J Vasc Surg"},{"issue":"2","key":"1007_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1053\/meta.2003.50025","volume":"52","author":"K Goya","year":"2003","unstructured":"Goya K, Otsuki M, Xu X, Kasayama S. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism. 2003;52(2):192\u20138.","journal-title":"Metabolism"},{"issue":"6","key":"1007_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/00005344-199506000-00013","volume":"25","author":"M Isogaya","year":"1995","unstructured":"Isogaya M, Yamada N, Koike H, et al. Inhibition of restenosis by beraprost sodium (a prostaglandin I2 analogue) in the atherosclerotic rabbit artery after angioplasty. J Cardiovasc Pharmacol. 1995;25(6):947\u201352.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"1007_CR21","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/cvr\/cvv176","volume":"107","author":"JS McKean","year":"2015","unstructured":"McKean JS, Murray F, Gibson G, Shewan DA, Tucker SJ, Nixon GF. The cAMP-producing agonist beraprost inhibits human vascular smooth muscle cell migration via exchange protein directly activated by cAMP. Cardiovasc Res. 2015;107(4):546\u201355.","journal-title":"Cardiovasc Res"},{"issue":"10 Pt 1","key":"1007_CR22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0895-7061(97)00311-7","volume":"10","author":"SP Glasser","year":"1997","unstructured":"Glasser SP, Arnett DK, McVeigh GE, et al. Vascular compliance and cardiovascular disease: a risk factor or a marker? Am J Hypertens. 1997;10(10 Pt 1):1175\u201389.","journal-title":"Am J Hypertens"},{"issue":"8","key":"1007_CR23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1161\/01.ATV.16.8.978","volume":"16","author":"S Lehto","year":"1996","unstructured":"Lehto S, Niskanen L, Suhonen M, R\u00f6nnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16(8):978\u201383.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"1007_CR24","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1161\/ATVBAHA.116.306717","volume":"36","author":"CY Ho","year":"2016","unstructured":"Ho CY, Shanahan CM. Medial Arterial Calcification: An Overlooked Player in Peripheral Arterial Disease. Arterioscler Thromb Vasc Biol. 2016;36(8):1475\u201382.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"1007_CR25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1093\/eurheartj\/ehu163","volume":"35","author":"P Lanzer","year":"2014","unstructured":"Lanzer P, Boehm M, Sorribas V, et al. Medial vascular calcification revisited: review and perspectives. Eur Heart J. 2014;35(23):1515\u201325.","journal-title":"Eur Heart J"},{"issue":"5","key":"1007_CR26","doi-asserted-by":"publisher","first-page":"e000481","DOI":"10.1161\/JAHA.113.000481","volume":"2","author":"M Rogers","year":"2013","unstructured":"Rogers M, Goettsch C, Aikawa E. Medial and intimal calcification in chronic kidney disease: stressing the contributions. J Am Heart Assoc. 2013;2(5):e000481.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"1007_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.plefa.2007.05.004","volume":"76","author":"T Nakayama","year":"2007","unstructured":"Nakayama T, Masubuchi Y, Kawauchi K, et al. Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction. Prostaglandins Leukot Essent Fatty Acids. 2007;76(6):309\u201314.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"4","key":"1007_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/ACI.0000000000000374","volume":"17","author":"G Cortellini","year":"2017","unstructured":"Cortellini G, Caruso C, Romano A. Aspirin challenge and desensitization: how, when and why. Curr Opin Allergy Clin Immunol. 2017;17(4):247\u201354.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"10","key":"1007_CR29","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0735-1097(03)00299-7","volume":"41","author":"ER Mohler 3rd","year":"2003","unstructured":"Mohler ER 3rd, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol. 2003;41(10):1679\u201386.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01007-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01007-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01007-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T20:11:16Z","timestamp":1648930276000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01007-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01007-5","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,2]]},"assertion":[{"value":"12 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles of the Helsinki declaration and was approved by the institutional review board of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. Signed informed consents for participation were obtained from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Signed informed consents for publication were obtained from all the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}